<DOC>
	<DOCNO>NCT00023348</DOCNO>
	<brief_summary>Primary Objectives : 1 ) To determine proportion patient HIV-related tuberculosis abnormal pharmacokinetic parameter isoniazid rifabutin . Secondary Objectives : 1 . To determine risk factor abnormal pharmacokinetic parameter isoniazid rifabutin . 2 . To evaluate correlation pharmacokinetic parameter isoniazid rifabutin occurrence toxicity attribute antituberculous therapy . 3 . To evaluate correlation pharmacokinetic parameter isoniazid rifabutin efficacy TB therapy . 4 . To define correlate phenotypic INH acetylator status result genotypic acetylator data obtain parent trial .</brief_summary>
	<brief_title>TBTC Study 23A : Pharmacokinetics Intermittent Isoniazid Rifabutin HIV-TB</brief_title>
	<detailed_description>This study seek enroll every eligible patient enrol TBTC Study 23 . Consenting patient ask undergo measurement isoniazid ( receive ) , rifabutin 25-OH desacetyl rifabutin level time point study steady state rifabutin level expect achieve ( least two week follow start rifabutin ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion : 1 . Patient enrol TBTC Study 23 2 . Informed consent Exclusion : 1 . Severe anemia ( Hct &lt; 25 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>